How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Slides:



Advertisements
Similar presentations
APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Advertisements

Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.
Department of Neurology, Mayo Clinic Arizona
Alzheimer’s Disease Edwin Onattu P. 3.
Management of Early Dementia Dr Eleanor Mullan Consultant Psychiatrist Mental Health Services for Older People South Lee, Cork Feb 2011.
Martha Stearn, MD Institute for Cognitive Health St John’s Medical Center Jackson, Wyoming.
AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
BERG SYMPOSIUM WASHINGTON UNIVERSITY SEPT 2003 MICHAEL W WEINER MD.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Pathology and Treatment
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.
Risk of Developing Alzheimer’s Disease in Persons with MCI
PET AND DEMENTIA Gary W. Small, M.D. Parlow-Solomon Professor on Aging Professor of Psychiatry and Biobehavioral Sciences Director, Center on Aging Director,
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
ALZHEIMER’S PART 2. AD VIDEO
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
Alzheimer’s Disease Landscape
Mild Cognitive Impairment
By: Tasso Skountzouris David Schiano. General Description  Alzheimer’s is one the most common form of Dementia  Dementia causes a loss of brain function.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
Menopause and the Brain: Lifting the Fog Majid Fotuhi, MD PhD.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.
Dementia: Delivering the Diagnosis Daniel D. Christensen, M.D. Clinical Professor of Psychiatry Clinical Professor of Neurology Adjunct Professor of Pharmacology.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 33 Delirium and Dementia.
Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.
Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.
1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.
Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology Alzheimer’s Disease Avi Gandhi (2009)
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
How To Grow Your Hippocampus in Three Months Majid Fotuhi, MD PhD Founder and Chief Medical Officer NeurExpand Brain Center Nothing to disclose.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
A Lifetime of Quality Care That’s Convenient & Complete Alzheimer’s Disease Robert Grimshaw, MD FACP A Lifetime of Quality Care That’s Convenient & Complete.
Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.
Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.
Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.
CAROLINE HARADA, M.D. ASSOCIATE PROFESSOR OF MEDICINE UAB DIVISION OF GERONTOLOGY, GERIATRICS, AND PALLIATIVE CARE NOVEMBER 2013 Dementia.
Epidemiology of Alzheimer’s Disease
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
Alabama Brief Cognitive Screener (ABCs)
Alzheimer's disease M O Jamali, H Saeed & T Mathew.
Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Kynnera Stephenson Lubbock Christain University \.
Alzheimer's disease 蕭尚益 丁唯洋 蔡欣容. Outline introductionDisease mechanismPreventConclusion.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.
Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.
COGNITIVE DEVELOPMENT IN LATE ADULTHOOD CHAPTER 18 Lecture Prepared by: Dr. M. Sawhney.
Alzheimer’s Disease: 진단과 치료
The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.
DEGENERATIVE DISEASES is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether.
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
Laura Baker, PhD Internal Medicine, Neurology, & Public Health Sciences Wake Forest School of Medicine Winston-Salem, NC USA.
Rosa Maria Moresco University of Milan Bicocca
Dementia.
What will it take to develop an effective Alzheimer’s drug?
Cognitive Disorders and Aging
Modifying Disease Course in Alzheimer's Disease
Early Dementia Distinguishing AD From MCI
Chapter 30 Delirium and Dementia
Probing the Biology of Alzheimer's Disease in Mice
Baseline Characteristics of the Subjects
Ongoing Research With Vascular Risk Factors and the RAS in Individuals at Risk for AD Whitney Wharton, PhD Assistant Professor,
Presentation transcript:

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral Sciences David Geffen School of Medicine University of California, Los Angeles Los Angeles, California

Keeping Our Brains Young Time Memory Ability No Intervention Early Intervention

Alzheimer’s Disease Is the End Result of Brain Aging Small. The Memory Bible. New York, NY: Hyperion; Mild Cognitive Impairment Alzheimer’s Disease Age-Associated Memory Impairment Time Cognitive Function

Risk Factors for Brain Aging  Confirmed  Age  Family history  APOE-4 gene  Possible  Other genes  Head trauma  Lower educational achievement  Chronic stress Small. Br Med J. 2002;324:

Protective Factors for Brain Aging  Aerobic exercise  Estrogen  Elevated homocysteine  Antiinflammatory drugs  Antioxidants  Low-fat diet  Wine Small. Br Med J. 2002;324:

Time Cognitive Function Cognitive Stress Test Amyloid Imaging Current Initiation of Therapy FDG-PET Genetic Risk Presymptomatic Stages AD Early Detection of Alzheimer’s Disease Onset

Cognitive Stress Test With fMRI  Functional brain measures during memory performance may uncover subtle brain dysfunction not observed during mental rest (cf, treadmill ECG for cardiac disease)  Combine neuroimaging and APOE-4 measures of genetic risk in order to identify abnormalities that may predict future cognitive decline Bookheimer et al. N Engl J Med. 2000;343:

Possible Outcomes Using PET as a Surrogate Marker in AAMI Clinical Trials APOE 3/4 and Active Drug APOE 3/4 and Placebo Baseline Follow-up AAMI = age-associated memory impairment. Small. The Memory Bible. New York, NY: Hyperion; Time Metabolic Function

Time Cognitive Function Early Detection and Intervention: Ongoing Placebo-Controlled Trials AD AAMI MCI 1. Celecoxib 2. Donepezil 1. Donepezil vs Vitamin E 2. Donepezil vs Ginkgo 3. Donepezil vs Estrogen 4. Rivastigmine 5. Galantamine 6. Rofecoxib 1° Outcome: clinical exam 1° Outcome: PET + APOE-4 Small. The Memory Bible. New York, NY: Hyperion; 2002.

UCLA School of Medicine. 100% 0% Min. Max. 100% 0% Min. Max. MRI FDDNP PET FDG PET AD Patient Control

MMSE Scores vs Residence Time (RT) Values Hypothetical Stages V-VI Hypothetical Stages III-IV Hypothetical Stages I-II Residence Time MMSE Controls AD Shoghi-Jadid et al. Am J Geriatr Psychiatry. 2002;10:24-35.

Autoradiography PETMRI Confocal Fluorescence Microscopy Plaques (SP) and tangles (NFT) NFT Plaques and tangles [ 18 F]FDDNP  The Barrio Lab. UCLA School of Medicine Min. Activity Max. Activity AD Patient: Comparison of in-vivo and in-vitro Experiments SP striatum

Cognitive Reserve fMRI Neuronal Function FDG-PET Plaque/Tangle Load FDDNP-PET Regional Atrophy Structural MRI Genetic Risk Profile NeuropsychologicalProfile DiagnosisTreatment Using Information From Multiple Sources to Improve Early Diagnosis and Treatment

Keeping Our Brains Young  Minimize stress  Get regular physical exercise  Eat a healthy brain diet  Choose a lifestyle that protects your brain  Use medicines wisely  Train your brain with mental aerobics

ConclusionsConclusions  Brain aging begins early in adult life  Early detection and prevention strategies may be useful in decelerating brain aging  Available symptomatic treatments offer benefit early in the course of dementia and may prove effective for milder cognitive deficits